Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal Article (Journal Article)

Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the function of the affected organs by targeting the abnormal plasma cell clone and slowing deposition of amyloid fibrils. The NCCN Guidelines for SLCA provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated SLCA.

Full Text

Duke Authors

Cited Authors

  • Kumar, SK; Callander, NS; Adekola, K; Anderson, LD; Baljevic, M; Campagnaro, E; Castillo, JJ; Costello, C; D'Angelo, C; Devarakonda, S; Elsedawy, N; Garfall, A; Godby, K; Hillengass, J; Holmberg, L; Htut, M; Huff, CA; Hultcrantz, M; Kang, Y; Larson, S; Lee, HC; Liedtke, M; Martin, T; Omel, J; Rosenberg, A; Sborov, D; Valent, J; Berardi, R; Kumar, R

Published Date

  • January 2023

Published In

Volume / Issue

  • 21 / 1

Start / End Page

  • 67 - 81

PubMed ID

  • 36652935

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2023.0001


  • eng

Conference Location

  • United States